Abstract
Andes virus, an orthohantavirus endemic to South America, causes severe hantavirus cardiopulmonary syndrome associated with human-to-human transmission. No approved treatments or vaccines against this virus are available. We show that a combined treatment with 2 monoclonal antibodies protected Syrian hamsters when administered at midstage or late-stage disease.
Highlights
Andes virus, an orthohantavirus endemic to South America, causes severe hantavirus cardiopulmonary syndrome associated with human-to-human transmission
Hantavirus cardiopulmonary syndrome (HCPS) is a severe disease caused by infection with pathogenic New World orthohantaviruses, including Andes virus (ANDV)
Our results demonstrate that the human monoclonal antibodies (mAbs) cocktail containing JL16 and MIB22 is able to completely or partially protect Syrian hamsters against lethal
Summary
Passive transfusion of specific monoclonal antibodies (mAbs) protected animals from ANDV challenge in the lethal Syrian hamster disease model [9,10,11]. All of these data suggest an important role for neutralizing antibodies in controlling orthohantavirus infections in vivo. We determined the efficacy of the mAb cocktail administered at 5 and 9 days dpi (5+9) to a treatment group (n = 12), compared with a control group (n = 12) treated with isotype antibody (Figure 1, panel A). The single surviving control animal showed clinical signs of disease that scored
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
